An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) (VITALITY)
19. mars 2019 oppdatert av: AbbVie
For public health purposes disability is becoming increasingly important as an outcome measure. Despite this, there are few data on the effectiveness of adalimumab on disability outcomes in patients with immune-mediated inflammatory diseases (IMIDs), particularly in the Phase IV setting. There are even less data available in New Zealand, which did not have the opportunity to participate to a major extent in large, multinational, Phase III pivotal studies of adalimumab in IMIDs.
The World Health Organisation Disability Assessment Schedule (WHODAS) 2.0 is a simple, validated, free and easy-to-use generic assessment instrument for health and disability. It is applicable across cultures, in all adult populations. It is a responsive measure that can show what difference a treatment makes.
Results from study of effect of adalimumab on WHODAS scores and other patient-reported outcomes (PROs) of work activity and well-being will be of interest to a variety of stakeholders in the healthcare system including patients, healthcare practitioners and payers.
Studieoversikt
Status
Fullført
Forhold
Studietype
Observasjonsmessig
Registrering (Faktiske)
168
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 75 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
Subjects will be males and/or females who are attending a routine clinical visit and meet all of the inclusion criteria and none of the exclusion criteria.
Beskrivelse
Inclusion Criteria:
- Patients with a diagnosis of rheumatoid arthritis, Crohn's disease or psoriasis who have made a decision with their physician to commence treatment with adalimumab in accordance with routine medical practice and with the approved adalimumab New Zealand Datasheet.
- Patients who have been evaluated for tuberculosis risk factors/exposure for active/latent tuberculosis infection (per local requirements and according to the approved adalimumab New Zealand Datasheet).
- Adult subjects, 18-75 years old, who have voluntarily signed and dated an informed consent form prior to any study-specific procedures.
Exclusion Criteria:
- Previous treatment with adalimumab.
- Previous treatment with any biologic.
- Severe infection including sepsis, active tuberculosis or opportunistic infection.
- Moderate to severe heart failure (New York Heart Association Class II/III).
- Concurrent administration with anakinra.
- Hypersensitivity to adalimumab or its excipients.
- Any condition that in the opinion of the investigator would compromise the subject's well-being or ability to perform the study requirements.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Crohn's Disease
Participants with Crohn's disease.
All participants will receive at least 3 months of treatment with adalimumab.
Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
|
|
Rheumatoid Arthritis
Participants with rheumatoid arthritis.
All participants will receive at least 3 months of treatment with adalimumab.
Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
|
|
Psoriasis
Participants with psoriasis.
All participants will receive at least 3 months of treatment with adalimumab.
Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 Across All Indications
Tidsramme: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in WHODAS 2.0 Response Score at Month 2 Across All Indications
Tidsramme: Baseline, Month 2
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 2
|
|
Change From Baseline in WHODAS 2.0 Response Score at Month 4 Across All Indications
Tidsramme: Baseline, Month 4
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 4
|
|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Crohn's Disease
Tidsramme: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 In Participants With Psoriasis
Tidsramme: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
|
Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Rheumatoid Arthritis
Tidsramme: Baseline, Month 6
|
WHODAS 2.0 is a measures health and disability across cultures in all adult populations by assessing the same individual before and after the intervention across 12 items, covering the following 6 domains: cognition, mobility, self-care, getting along, life activities and participation.
Scores assigned to each of the items (none=0, mild=1, moderate=2, severe=3, and extreme=4) are summed.
Scores can range from 0 to 48.
Persons scoring 10 to 48 are likely to have clinically significant disability.
|
Baseline, Month 6
|
|
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Absenteeism
Tidsramme: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
|
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Presenteeism
Tidsramme: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
|
Change From Baseline in WPAI:GH 2.0 Score at Month 6 Across All Indications: Work Productivity Loss
Tidsramme: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
|
Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Activity Impairment
Tidsramme: Baseline, Month 6
|
WPAI:GH is a 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities.
The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
The questionnaire specifies responses for the previous 7 days.
|
Baseline, Month 6
|
|
Change From Baseline in K10 at Month 6 Across All Indications
Tidsramme: Baseline, Month 6
|
The K10 is intended to yield a global measure of distress based on a questionnaire about anxiety and depressive symptoms that a person has experienced in the most recent 4 week period.
The K10 scale involves 10 questions about emotional states each with a 5-level response scale.
Each item is scored from 1=none of the time to 5=all of the time.
Scores of the 10 items are then summed, yielding a minimum score of 10 and a maximum score of 50.
Low scores indicate low levels of psychological distress and high scores indicate high levels of psychological distress.
|
Baseline, Month 6
|
|
Change From Baseline in Flourishing Scale at Month 6 Across All Indications
Tidsramme: Baseline, Month 6
|
The Flourishing Scale is a brief 8-item summary measure of the respondent's self-perceived success in important areas such as relationships, self-esteem, purpose, and optimism.
The scale provides a single psychological well-being score.
Participants are asked to respond to 8 statements using a scale of 1 (strongly disagree) and 7 (strongly agree) for each item.
The possible range of scores is from 8 (lowest possible) to 56 (highest possible), with higher scores representing more psychological resources and strengths.
|
Baseline, Month 6
|
|
Change From Baseline in Subjective Vitality Scale at Month 6 Across All Indications
Tidsramme: Baseline, Month 6
|
The Subjective Vitality Scale assesses the state of feeling alive and alert to having energy available to the self.
Patients respond to eight prompts, with a response ranging from 1=strongly disagree to 7=strongly agree.
The sum of the scores is calculated with a higher score indicating a better condition.
The total score ranges from 8 to 56 with a higher score indicating a better condition.
|
Baseline, Month 6
|
|
Change From Baseline in HAQ-DI Score at Month 6 in Participants With Rheumatoid Arthritis
Tidsramme: Baseline, Month 6
|
HAQ-DI measures functional status in rheumatic diseases.
It has 20 items, and asks patients to report the degree of difficulty faced in several areas of their life including: dressing and grooming, arising, eating, walking, hygiene, reach, grip, activities based on the previous week on a scale from 0 (without any difficulty) to 3 (cannot be done at all).
It also asks the participant to rate their pain and health in the previous week.
Scores on each task are summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high-dependency disability).
|
Baseline, Month 6
|
|
Change From Baseline in SIBDQ Score at Month 6 in Participants With Crohn's Disease
Tidsramme: Baseline, Month 6
|
The SIBDQ is a simple validated, 10-item questionnaire designed to find out how the patient has been feeling in the previous 2 weeks.
QoL is measured in 4 domains: bowel symptoms, emotional health, systemic systems and social function.
Participants respond to questions ranging from 1=all of the time to 7=none of the time.
Scores are added together, with higher scores indicating a better health-related QoL.
Total scores range from 10 (poor QoL) to 70 (good QoL).
|
Baseline, Month 6
|
|
Change From Baseline in DLQI Score at Month 6 in Participants With Psoriasis
Tidsramme: Baseline, Month 6
|
The DLQI measures 10 items covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, to determine how much the patients skin problem affected their life in the past week.
Participants respond to the questions with 'very much,' 'a lot,' 'a little,' or 'not at all.'
The scores are added together, and the impact on QoL is banded as follows: 0-1=no effect on participant's life; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.
|
Baseline, Month 6
|
|
Number of Participants Remaining on Treatment at Month 6
Tidsramme: Month 6
|
The number of participants at 6 months who remained on adalimumab, having satisfied the requirements for application for renewal of subsidy by special authority.
|
Month 6
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
6. juli 2015
Primær fullføring (Faktiske)
5. desember 2017
Studiet fullført (Faktiske)
5. desember 2017
Datoer for studieregistrering
Først innsendt
20. mai 2015
Først innsendt som oppfylte QC-kriteriene
20. mai 2015
Først lagt ut (Anslag)
22. mai 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
19. juni 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
19. mars 2019
Sist bekreftet
1. januar 2018
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P15-345
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Ubestemt
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .